Alvotech and STADA enter commercialisation agreement for biosimilars in EU

Alvotech and STADA announce agreement for the commercialisation of seven biosimilars in all key European markets and selected markets outside Europe. Under the agreement, Alvotech will be responsible for the development, registration and supply of the biosimilars, with STADA responsible for commercialisation.